Treatment of Supine Hypertension in Autonomic Failure (CPAP)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorVanderbilt University Medical Center
About this trial
Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with autonomic failure and with supine hypertension from all races
Disqualifiers
All medical students
Pregnant women
High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction)
History of serious allergies or asthma.
Trial design
Design model
Crossover
Treatments tested in this trial
continuous positive airway pressure (CPAP)
DeviceContinuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
Placebo
DrugPlacebo pill or patch. Single dose
Treatment groups
12 Participants
are divided into 2 treatment groupsGroup A: Placebo pill or patch or sham CPAPPlacebo comparator 1 intervention
Group B: CPAP (continuous positive airway pressure)Active comparator 1 intervention
Trial outcomes
Primary outcomes
1
Supine Systolic Blood Pressure
change in supine systolic blood pressure from baseline
Time frame
12 hoursSecondary outcomes
1
Urinary volume
Nocturnal urinary volume
Time frame
12 hoursSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov